



The first synthesis of a cyclic dihydroxyacetone phosphate, a new molecule of biological importance

Shyamaprosad Goswami* and Avijit Kumar Adak

Department of Chemistry, Bengal Engineering College (Deemed University), Howrah 711 103, West Bengal, India


Received 21 August 2001; revised 23 October 2001; accepted 14 November 2001

Abstract—A six-membered cyclic dihydroxyacetone phosphate (CDHAP) **3** (2-oxo-2-phenoxy-2λ⁵-[1,2,3]-dioxaphosphinane-5-one) which is a new and interesting molecule of biological interest has been synthesised for the first time. Though dihydroxyacetone phosphate (DHAP) **2** is very well known and is the precursor for enzymatic synthesis of sugars, the six-membered cyclic dihydroxyacetone phosphate and its synthesis have not been reported to our knowledge. © 2002 Elsevier Science Ltd. All rights reserved.

Dihydroxyacetone (DHA) exists as a dimer **1**. Normally, dihydroxyacetone phosphate (DHAP) **2** is synthesised enzymatically as well as chemically. DHAP has been used extensively in organic synthesis for enzymatic aldol reactions in the synthesis of sugars.¹ Six-membered cyclic phosphates are important constituents present in a number of biologically important molecules, e.g. cyclic adenosine phosphate² and Form Z (a precursor) of molybdenum cofactor.^{3,4} Rajagopalan and co-workers^{5,6} have shown that the substrate of Form Z is an α-phosphorylated ketone where the phosphate is a part of the six-membered ring. In our synthetic studies⁷ on the molybdenum cofactor, we were interested to have an efficient synthesis of CDHAP **3**. We report here the synthesis of the six-membered cyclic phosphate **3** and also the *exo*-methylene analogue **4**. We utilised a low temperature ozonolysis reaction for the synthesis of **3** from a stable phosphate triester 5-methylene-2-oxo-2-phenoxy-[1,2,3]-dioxaphosphorinane **4**. The β-hydroxyl group of Form Z, may be generated by NaBH₄ reduction of the keto group of CDHAP.


The DHA dimer **1** has been chemically phosphorylated to **2** via POCl₃,⁸ (PhO)₂P(O)Cl⁹ and also by Wong's improved method.¹ We reacted **1** with (*p*-NO₂-PhO)P(O)Cl₂ in various solvents containing Et₃N such as CH₂Cl₂, dioxan, CH₃CN and also in pyridine, but the yield was very poor (5–10%) in all the cases due to the notorious insolubility of **1** in the solvent used. We reasoned that **5** could be used as a more suitable starting material for making CDHAP **3** via conventional methods. The *exo*-methylene function could easily be converted into a keto group by ozonolysis at low temperature and under neutral conditions in which the cyclic phosphate moiety should survive.

We thus report here our successful approach to prepare **3** by this new and efficient method (Scheme 1) in good yield. High dilution coupling of **5** and (PhO)P(O)Cl₂ in dry CH₂Cl₂ and Et₃N afforded a thick, light yellow liquid **4**, which on ozonolysis gave the pale brown semi-solid **3** in 70% overall yield. Compound **4** was also made via the formation of intermediate **6** by the reaction of **5** with POCl₃ or PCl₅. Intermediate **6** was not



Keywords: dihydroxyacetone dimer; cyclic phosphate; molybdenum cofactor; cyclic keto phosphate; ozonolysis.

* Corresponding author. E-mail: spgoswamical@yahoo.com



Scheme 1.

isolated, but directly converted to compound **4** by reaction with phenol in dry CH_2Cl_2 at room temperature. However, the $(\text{PhO})\text{P}(\text{O})\text{Cl}_2$ route was found to be more efficient for the synthesis of **4**. Compounds **3** and **4** were well characterised¹⁰ by spectroscopic means including ^{31}P NMR.

A solid state X-ray study¹¹ of 2-oxo-2-phenoxy-1,2,3-dioxaphosphorinane **7** ($\text{R}=\text{H}$) revealed that the phenoxy substituent favours an axial orientation in the chair conformation. In **3** and **4**, the phosphorus is more strongly coupled to the equatorial protons ($^3J_{\text{P-H (eq.)}} = 18.73$ Hz for **3** and 18.91 Hz for **4**) compared to the axial protons ($^3J_{\text{P-H (ax.)}} < 4.5$ Hz both for **3** and **4**) (Fig. 1 and Fig. 2). These findings are consistent with the $^3J_{\text{P-H}}$ coupling constants for axial and equatorial protons in **7** ($\text{R}=\text{CH}_3$)¹² and those found in other dioxaphosphorinane ring systems¹³ and thus, it is likely that **3** and **4** exist as a single conformer at room temperature.

In conclusion, we have developed a new route for the synthesis of a cyclic dihydroxyacetone phosphate. The new compounds, e.g. 5-methylene-2-oxo-2-phenoxy-[1,2,3]-dioxaphosphorinane and CDHAP are promising synthons for the synthesis of keto sugars or analogues attached to different groups having biological importance.




Figure 1. ^1H decoupled ^{31}P NMR (top) and ^1H undecoupled ^{31}P NMR (bottom) of **3** at 22°C .




Figure 2. ^1H decoupled ^{31}P NMR (top) and ^1H undecoupled ^{31}P NMR (bottom) of **4** at 22°C .

Acknowledgements

We thank C.S.I.R., Govt. of India for financial support and Bose Institute, Kolkata for the paid facility of 500 MHz NMR. We also acknowledge Professor S. Ghosh for the facility of Welbush Ozonapor instrument at the Department of Organic Chemistry at IACS, Kolkata.

References

- Pederson, R. L.; Esker, J.; Wong, C. H. *Tetrahedron* **1991**, *47*, 2643–2648 and references cited therein.
- Lipkin, D.; Cook, W. H.; Markham, R. *J. Am. Chem. Soc.* **1959**, *81*, 6198.
- Hille, R. *Chem. Rev.* **1996**, *96*, 2757–2816.
- Pateman, J. A.; Coves, D. J.; Rever, B. M.; Roberts, D. B. *Nature* **1964**, *201*, 58.
- Johnson, J. L.; Wuebbens, M. M.; Rajagopalan, K. V. *J. Biol. Chem.* **1989**, *264*, 13440–13447.
- Wuebbens, M. M.; Rajagopalan, K. V. *J. Biol. Chem.* **1993**, *268*, 13493–13498.
- (a) Pilato, R. S.; Erickson, K. A.; Greaney, M. A.; Stiefel, E. I.; Goswami, S. P.; Kilpatrick, L.; Spiro, T. G.; Taylor, E. C.; Rhiengold, A. L. *J. Am. Chem. Soc.* **1991**, *113*, 9372–9374; (b) Goswami, S. P. *Heterocycles* **1993**,

- 35, 1552–1572; (c) Goswami, S. P.; Adak, A. K. On asymmetric synthesis of Form Z, a precursor to molybdenum co-factor. *International Symposium on Current Trends in Drug Discovery Research*, CTDDR-2001 11–15th Feb, CDRI, Lucknow, India, 2001; Abs # OP-XVIV-5.
8. Effenberger, F.; Strub, A. *Tetrahedron Lett.* **1987**, 28, 1641.
9. Colbran, R. L.; Jones, J. K. N.; Matheson, N. K.; Rozema, I. *Carbohydr. Res.* **1967**, 4, 352.
10. Spectral analysis: For **3**: ^1H NMR (CDCl_3 , 300 MHz): 7.34–7.29 (m, 3H), 7.18–7.15 (m, 2H), 4.84–4.60 (m, 4H). ^{13}C NMR (CDCl_3 , 500 MHz): 202.09 (C=O), 133.43 (CH), 130.38 (CH), 125.84 (CH), 120.02 (d, $J=5.1$ Hz, CH), 118.26 (CH), 116.42 (CH), 72.39 (d, $^2J_{\text{P-C}}=7.3$ Hz, $2\times\text{CH}_2$). ^1H decoupled ^{31}P NMR (CDCl_3 , 500 MHz): 5.20. Mass (FD): 228 (M^+), 36%. For **4**: ^1H NMR (CDCl_3 , 500 MHz): δ 7.28 (d, 2H, $J=8.0$ Hz), 7.19 (d, 2H, $J=8.0$ Hz), 7.12 (t, 1H, $J=7.3$ Hz), 5.23 (d, 2H, $J=9.4$ Hz), 4.89 (dd, 2H, $J_{\text{H-H}}=12.5$ Hz, $J_{\text{P-O-C-H}}=4.5$ Hz (ax.)), 4.72 (dd, 2H, $J_{\text{H-H}}=12.8$ Hz, $J_{\text{P-O-C-H}}=19.0$ Hz (eq.)). ^{13}C NMR (CDCl_3 , 500 MHz): 150.79 (d, $J_{\text{P-C}}=6.7$ Hz, $=\text{CH}_2$), 135.12 (d, $^3J_{\text{P-C}}=9.6$ Hz, C), 130.31 (CH), 125.61 (d, $J=1$ Hz, CH), 120.02 (d, $J=5.1$ Hz, CH), 117.89 (CH), 72.2 (d, $^2J_{\text{P-C}}=7.5$ Hz, $2\times\text{CH}_2$). ^1H decoupled ^{31}P NMR (CDCl_3 , 500 MHz): 4.78. Mass (FAB): 227.1 (MH^+).
11. Geise, H. J. *Rec. Trav. Chim.* **1967**, 86, 362.
12. Hall, L. D.; Malcolm, R. B. *Can. J. Chem.* **1972**, 2092–2101.
13. Hulst, R.; Visser, J. M.; Koen de Vries, N.; Zijlstra, R. W. J.; Kooijman, H.; Smeets, W.; Speck, A. L.; Feringa, B. L. *J. Am. Chem. Soc.* **2000**, 122, 3135–3150 and references cited therein.